

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **June 6, 2016**

HELIUS MEDICAL TECHNOLOGIES, INC.

(Exact Name of Registrant as Specified in Charter)

Wyoming
(State or Other Jurisdiction
of Incorporation)

000-55364
(Commission
File Number)

36-4787690
(IRS Employer
Identification No.)

Suite 400, 41 University Drive
Newtown, Pennsylvania
(Address of Principal Executive Offices)

18940
(Zip Code)

Registrant's telephone number, including area code **(215) 809-2018**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Item 8.01 Other Events.

On June 6, 2016, Helius Medical Technologies, Inc. issued a press release, a copy of which is attached hereto as Exhibit 99.1.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 6, 2016

HELIUS MEDICAL TECHNOLOGIES, INC.

/s/ Joyce LaViscount

By: Name: Joyce LaViscount

Title: Chief Financial Officer

Exhibit Index

<u>Exhibit Number</u>	<u>Description</u>
---------------------------	--------------------

99.1	Press release, dated June 6, 2016.
------	--



Helius Medical Announces Proceeds of \$1.4 Million from Exercise of Warrants

THIS NEWS RELEASE IS INTENDED FOR IMMEDIATE RELEASE

NEWTOWN, PA – June 6, 2016 – Helius Medical Technologies, Inc. (TSX: HSM, and OTCQB: HSDT) ("Helius" or the "Company") a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, is pleased to announce that it received proceeds of CDN \$1,825,600 (approximately US\$1,409,947) from the exercise of certain warrants issued in 2014, all of which was received after the Company's fiscal year end on March 31, 2016.

The warrants expired on May 30, 2016 and were originally issued in connection with the Company's private placement of subscription receipts that closed on May 30, 2014. On June 13, 2014, each subscription receipt automatically converted, for no additional consideration, into one common share and one-half of one common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitled the holder thereof to purchase one additional share of common stock at a price of CDN \$1.00 prior to expiration on May 30, 2016.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or qualified under any state securities laws or the laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.

About the PoNST™

The PoNST™ device is a non-invasive means for delivering neurostimulation through the tongue. The PoNST™ therapy is currently being studied in the United States and Canada for the treatment of balance disorder for subjects with mild to moderate Traumatic Brain Injury.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a medical technology company focused on neurological wellness. Helius seeks to develop, license and acquire unique and non-invasive platform technologies that amplify the brain's ability to heal itself. Helius intends to file for FDA clearance for the PoNST™ device. For more information, please visit www.heliusmedical.com.

###

CONTACT

Helius Medical Technologies

Corporate Contact

Brian Bapty, 604-652-3950

bbapty@heliusmedical.com

Investor Relations:

778-588-7144

info@heliusmedical.com

Media Contact:

Becky Kern, 914-772-2310

media@heliusmedical.com
